X-136207910-C-G
Position:
Variant summary
Our verdict is Likely pathogenic. Variant got 8 ACMG points: 8P and 0B. PM2PP3_StrongPP5_Moderate
The NM_001159699.2(FHL1):c.498C>G(p.Cys166Trp) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★).
Frequency
Genomes: not found (cov: 23)
Consequence
FHL1
NM_001159699.2 missense
NM_001159699.2 missense
Scores
13
3
1
Clinical Significance
Conservation
PhyloP100: 0.0320
Genes affected
FHL1 (HGNC:3702): (four and a half LIM domains 1) This gene encodes a member of the four-and-a-half-LIM-only protein family. Family members contain two highly conserved, tandemly arranged, zinc finger domains with four highly conserved cysteines binding a zinc atom in each zinc finger. Expression of these family members occurs in a cell- and tissue-specific mode and these proteins are involved in many cellular processes. Mutations in this gene have been found in patients with Emery-Dreifuss muscular dystrophy. Multiple alternately spliced transcript variants which encode different protein isoforms have been described.[provided by RefSeq, Nov 2009]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Likely_pathogenic. Variant got 8 ACMG points.
PM2
Very rare variant in population databases, with high coverage;
PP3
MetaRNN computational evidence supports a deleterious effect, 0.984
PP5
Variant X-136207910-C-G is Pathogenic according to our data. Variant chrX-136207910-C-G is described in ClinVar as [Likely_pathogenic]. Clinvar id is 943902.Status of the report is criteria_provided_single_submitter, 1 stars.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
FHL1 | NM_001159702.3 | c.450C>G | p.Cys150Trp | missense_variant | 5/8 | ENST00000394155.8 | NP_001153174.1 | |
FHL1 | NM_001159699.2 | c.498C>G | p.Cys166Trp | missense_variant | 4/6 | ENST00000370683.6 | NP_001153171.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
FHL1 | ENST00000394155.8 | c.450C>G | p.Cys150Trp | missense_variant | 5/8 | 5 | NM_001159702.3 | ENSP00000377710.2 | ||
FHL1 | ENST00000370683.6 | c.498C>G | p.Cys166Trp | missense_variant | 4/6 | 1 | NM_001159699.2 | ENSP00000359717.1 |
Frequencies
GnomAD3 genomes Cov.: 23
GnomAD3 genomes
Cov.:
23
GnomAD4 exome Cov.: 31
GnomAD4 exome
Cov.:
31
GnomAD4 genome Cov.: 23
GnomAD4 genome
Cov.:
23
ClinVar
Significance: Likely pathogenic
Submissions summary: Pathogenic:1
Revision: criteria provided, single submitter
LINK: link
Submissions by phenotype
X-linked myopathy with postural muscle atrophy Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jul 26, 2023 | In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. This variant disrupts the p.Cys150 amino acid residue in FHL1. Other variant(s) that disrupt this residue have been observed in individuals with FHL1-related conditions (PMID: 19171836, 20571991, 23169582, 25191266), which suggests that this may be a clinically significant amino acid residue. An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. ClinVar contains an entry for this variant (Variation ID: 943902). This missense change has been observed in individual(s) with X-linked dominant FHL1-related conditions (Invitae). It has also been observed to segregate with disease in related individuals. This variant is not present in population databases (gnomAD no frequency). This sequence change replaces cysteine, which is neutral and slightly polar, with tryptophan, which is neutral and slightly polar, at codon 150 of the FHL1 protein (p.Cys150Trp). - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
CADD
Uncertain
DANN
Uncertain
DEOGEN2
Pathogenic
.;D;.;T;.;D;D;.;D;.;D;.;.;D;.;D;.;.;D;D;.
FATHMM_MKL
Uncertain
D
LIST_S2
Uncertain
.;D;.;D;D;D;D;.;.;.;D;.;D;D;D;.;D;D;D;D;.
M_CAP
Pathogenic
D
MetaRNN
Pathogenic
D;D;D;D;D;D;D;D;D;D;D;D;D;D;D;D;D;D;D;D;D
MetaSVM
Pathogenic
D
MutationAssessor
Pathogenic
H;H;H;.;H;.;.;H;.;H;.;H;H;.;.;H;.;.;.;.;H
PrimateAI
Pathogenic
D
PROVEAN
Pathogenic
.;D;D;.;.;D;D;.;D;D;D;D;D;D;.;D;D;D;D;D;.
REVEL
Pathogenic
Sift
Pathogenic
.;D;D;.;.;D;D;.;D;D;D;D;D;D;.;D;D;D;D;D;.
Sift4G
Pathogenic
D;D;D;D;D;D;D;D;D;D;D;D;D;D;D;D;D;D;D;D;D
Polyphen
1.0
.;D;.;.;.;.;.;.;.;.;.;.;.;.;.;D;.;.;D;.;.
Vest4
MutPred
Loss of catalytic residue at T152 (P = 0.0915);Loss of catalytic residue at T152 (P = 0.0915);Loss of catalytic residue at T152 (P = 0.0915);Loss of catalytic residue at T152 (P = 0.0915);Loss of catalytic residue at T152 (P = 0.0915);Loss of catalytic residue at T152 (P = 0.0915);Loss of catalytic residue at T152 (P = 0.0915);Loss of catalytic residue at T152 (P = 0.0915);Loss of catalytic residue at T152 (P = 0.0915);Loss of catalytic residue at T152 (P = 0.0915);Loss of catalytic residue at T152 (P = 0.0915);Loss of catalytic residue at T152 (P = 0.0915);Loss of catalytic residue at T152 (P = 0.0915);Loss of catalytic residue at T152 (P = 0.0915);Loss of catalytic residue at T152 (P = 0.0915);Loss of catalytic residue at T152 (P = 0.0915);.;.;.;Loss of catalytic residue at T152 (P = 0.0915);Loss of catalytic residue at T152 (P = 0.0915);
MVP
MPC
1.7
ClinPred
D
GERP RS
Varity_R
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at